Additionally, the 36-month beta value for MIRA is 1.95. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for MIRA is 12.48M and currently, short sellers hold a 3.96% ratio of that float. The average trading volume of MIRA on May 08, 2025 was 1.17M shares.
MIRA) stock’s latest price update
Mira Pharmaceuticals Inc (NASDAQ: MIRA)’s stock price has dropped by -0.86 in relation to previous closing price of 1.16. Nevertheless, the company has seen a gain of 0.88% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-08 that With valuations confirmed by the board, MIRA advances strategic acquisition targeting obesity and nicotine dependence, which includes a $5 million contribution in cash or assets from SKNY to be transferred at closing. MIAMI, FLORIDA / ACCESS Newswire / May 8, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that its Board of Directors has approved the planned acquisition of SKNY Pharmaceuticals, Inc. (the “Merger”), following the completion of independent valuation reports on both companies.
MIRA’s Market Performance
Mira Pharmaceuticals Inc (MIRA) has experienced a 0.88% rise in stock performance for the past week, with a 38.55% rise in the past month, and a -1.71% drop in the past quarter. The volatility ratio for the week is 7.24%, and the volatility levels for the past 30 days are at 10.39% for MIRA. The simple moving average for the past 20 days is 12.33% for MIRA’s stock, with a -13.68% simple moving average for the past 200 days.
MIRA Trading at 11.57% from the 50-Day Moving Average
After a stumble in the market that brought MIRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.05% of loss for the given period.
Volatility was left at 10.39%, however, over the last 30 days, the volatility rate increased by 7.24%, as shares surge +35.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.65% upper at present.
During the last 5 trading sessions, MIRA rose by +0.88%, which changed the moving average for the period of 200-days by -77.05% in comparison to the 20-day moving average, which settled at $1.0236. In addition, Mira Pharmaceuticals Inc saw 0.88% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MIRA starting from Aminov Erez, who sale 55,410 shares at the price of $1.39 back on Nov 19 ’24. After this action, Aminov Erez now owns 1,105,790 shares of Mira Pharmaceuticals Inc, valued at $77,020 using the latest closing price.
Aminov Erez, the Chief Executive Officer of Mira Pharmaceuticals Inc, sale 44,590 shares at $1.27 during a trade that took place back on Nov 20 ’24, which means that Aminov Erez is holding 1,061,200 shares at $56,629 based on the most recent closing price.
Stock Fundamentals for MIRA
The total capital return value is set at -3.65. Equity return is now at value -238.90, with -199.93 for asset returns.
Currently, EBITDA for the company is -7.85 million with net debt to EBITDA at 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.99.
Conclusion
In conclusion, Mira Pharmaceuticals Inc (MIRA) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
